Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
NCT ID: NCT01213641
Last Updated: 2016-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
288 participants
OBSERVATIONAL
2009-11-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ilaris NIS in Korea
NCT06838143
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
NCT02334748
Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
NCT01170936
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
NCT01390350
Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy
NCT03936894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Little Rock Allergy and Asthma Clinic
Little Rock, Arizona, United States
Allergy Center at Brookstone
Columbus, Georgia, United States
Rush Presbyterian - St. Lukes Medical Center
Chicago, Illinois, United States
Novartis Investigative site
Bregenz, , Austria
Novartis Investigative site
Vienna, , Austria
Novartis Investigative site
Dresden, , Germany
Novartis Investigative site
Hamburg, , Germany
Novartis Investigative site
Heidelberg, , Germany
Novartis Investigative site
Herne, , Germany
Novartis Investigative site
Kiel, , Germany
Novartis Investigative site
Schweinfurt, , Germany
Novartis Investigative site
Tübingen, , Germany
Novartis Investigative site
Oslo, , Norway
Novartis Investigative site
Aarau, , Switzerland
Novartis Investigative site
Basel, , Switzerland
Novartis Investigative site
Geneva, , Switzerland
Novartis Investigative site
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Walker UA, Tilson HH, Hawkins PN, Poll TV, Noviello S, Levy J, Vritzali E, Hoffman HM, Kuemmerle-Deschner JB; CACZ885D2401 Study Investigators. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the beta-Confident Registry. RMD Open. 2021 May;7(2):e001663. doi: 10.1136/rmdopen-2021-001663.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CACZ885D2401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.